Cambridge, Mass.-based Dicerna Pharmaceuticals signed a research collaboration and licensing deal with Switzerland’s Roche for chronic hepatitis B virus therapies that could hit $1.67 billion.
A U.S. appeals court dealt a major blow to Merck & Co. Inc., upholding a ruling that threw out a $2.54 billion (£1.97 billion) jury verdict the drugmaker had won against Gilead Sciences Inc.
Gilead Sciences Inc. reported third-quarter results largely in line with Wall Street estimates, led by higher sales of the company’s HIV drugs, but deal-related costs led to a net loss.
The U.S. Food and Drug Administration identified 63 cases of worsening liver function in certain patients taking hepatitis C medicines made by drugmakers Merck & Co. Inc., Gilead Sciences Inc. and AbbVie Inc.
GlaxoSmithKline exercised an option to license Ionis Pharmaceuticals’ antisense medicines for people with chronic hepatitis B virus infection following positive Phase 2 results.
The only liver disease becoming more widespread in the U.S. is one driven by obesity and diabetes – NAFLD – even as other liver disorder types linked to drinking or hepatitis become less common.
AbbVie announced that the European Commission granted marketing authorization for Maviret (glecaprevir/pibrentasvir) to shorten once-daily treatment duration from 12 to 8 weeks in treatment-naïve, compensated cirrhotic, chronic hepatitis C patients with genotype 1, 2, 4, 5, and 6 infection.
A collaboration and license deal was inked with Gilead Sciences Inc. to develop and market a long-acting injectable HIV therapy using Durect Corp.’s SABER technology.
VBI Vaccines Inc. said a late-stage study testing the company’s hepatitis B vaccine against GlaxoSmithKline’s Engerix-B met the main goals.